(Q35181684)

7 August 2017

1 reference

title

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. (English)

1 reference

7 August 2017

0 references

Coagulation factor VIII

0 references

0 references

0 references

3

Blanchette VS

1 reference

7 August 2017

Sharathkumar A

1

1 reference

7 August 2017

Lillicrap D

2

1 reference

7 August 2017

Kern M

4

1 reference

7 August 2017

Leggo J

5

1 reference

7 August 2017

Stain AM

6

1 reference

7 August 2017

Brooker L

7

1 reference

7 August 2017

Carcao MD

8

1 reference

7 August 2017

publication date

1 June 2003

1 reference

Journal of Thrombosis and Haemostasis

7 August 2017

published in

1 reference

7 August 2017

volume

1

1 reference

7 August 2017

issue

6

1 reference

7 August 2017

page(s)

1228-1236

1 reference

Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Factor VIII inhibitor in mild haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Why do so many haemophilia A patients develop an inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Inhibitor of Factor VIII in Mild Haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Acquired circulating anticoagulants in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Factor VIII antibody in a patient with mild haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Continuous infusion therapy in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Advances toward gene therapy for hemophilia at the millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

High-titre factor VIII inhibitor in two children with mild haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Characterization of factor VIII antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

High titre inhibitor after continuous factor VIII administration for surgery in a young infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00230.X

10.1046/J.1538-7836.2003.00230.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference